CN105770520A - Medicine preparation used for treating coronary heart disease and application thereof - Google Patents
Medicine preparation used for treating coronary heart disease and application thereof Download PDFInfo
- Publication number
- CN105770520A CN105770520A CN201610127979.8A CN201610127979A CN105770520A CN 105770520 A CN105770520 A CN 105770520A CN 201610127979 A CN201610127979 A CN 201610127979A CN 105770520 A CN105770520 A CN 105770520A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical preparation
- fructus
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention relates to a medicine preparation used for treating the coronary heart disease and application thereof.The medicine preparation is prepared from rhizoma acori tatarinowii, borneol, cooked panax notoginseng, codonopsis pilosula, radix astragali, fructus arctii, ground beeltles, semen plantaginis, the root of red-rooted salvia, rhizoma cyperi, epimedium herbs, tribulus terrestris, coptes teeta, eupatorium fortunei, common yam rhizome, blighted wheat, perilepta dyeriana (Mast.) bremek, tamariskoid spikemoss herbs, wild rice roots and liquorice.The traditional Chinese medicine materials with different medicine properties are adopted, scientific compatibility is carried out, the materials are combined to achieve the effects of strengthening the foundation, treating the symptoms, strengthening the body and removing evil, monarch, minister, assistant and guide are complete, yin and yang balance is achieved, the emphasis is laid on function coordination of viscera such as the kidney, the heart, the liver and the spleen, and the medicine preparation reduces fat, resists coagulation, reduces blood viscosity and dissolves thrombus, the medicinal materials are matched to improve blood circulation, remove vasospasm and resist arteriosclerosis, and can effectively treat the cardiovascular system disease, the efficacy and the function are more comprehensive, and both symptoms and root causes are treated.
Description
Technical field
The present invention relates to for medicine treating coronary heart disease and application thereof, particularly to a kind of for pharmaceutical preparation treating coronary heart disease and application thereof, belong to field of medicaments.
Background technology
It is known that, coronary heart disease is called for short coronary heart disease, is a kind of modal heart disease, refers to the myocardial dysfunction and (or) organic disease that cause because of coronary stricture, blood supply insufficiency, therefore also known as ischemic heart desease, be the one of cardiovascular and cerebrovascular disease.Along with the quickening of modern life rhythm, cardiovascular and cerebrovascular disease increases year by year, and presents " sickness rate is high, disability rate is high, mortality rate height, relapse rate are high, complication is many ", the i.e. feature of " four is high by more than ".
Coronary heart disease refers to the myocardial dysfunction and (or) organic disease that cause because of coronary stricture, blood supply insufficiency, therefore also known as ischemic cardiomyopathy.Coronary heart disease is the heart disease of a kind of myocardial ischemia-anoxemia (angina pectoris) caused by coronary artery organic (atherosclerosis or dynamic property vasospasm) stenosis or occlusion or myocardial necrosis (myocardial infarction), also known as ischemic heart desease.The generation of coronary heart disease has substantial connection with the degree of coronary atherosclerosis and number, suffers from the disease such as hypertension, diabetes simultaneously, and obesity, bad life habits etc. are the principal elements bringing out this disease.Coronary heart disease is one of disease that whole world mortality rate is the highest, and according to World Health Organization's report of 2011, the coronary heart disease death number of China has arranged second place of the world.According to incompletely statistics, current China Patients with Cardiovascular/Cerebrovascular Diseases is close to 300,000,000, every year because the number that cardiovascular and cerebrovascular disease is dead reaches more than 300 ten thousand, and most commonly seen with coronary heart disease, it becomes one of key factor of harm health of people.Coronary heart disease is the most common type that atherosclerosis causes organ lesion, is the commonly encountered diseases of harm middle-aged and elderly people health, and presents rejuvenation tendency.The reason that arteria coronaria narrows is in that: too high, the cholesterol for a long time of the blood fat in blood is deposited on the inner membrance of coronary artery tube chamber with accumulating over a long period, form ground pattern speckle, it is coarse that the inner membrance making otherwise smooth becomes, soft tube wall becomes stiff, on this basis, the platelet broken also condense adhesion up, then just as river course by mud block, make coronary lumen narrow, even entirely shut.Freely even not entirely shutting of arteria coronaria, causes blood supply of cardiac muscle bad, and cardiac muscle can not get the nutrition of blood and necrosis is called myocardial infarction, and this is the performance that coronary heart disease is the most serious.Once cardiac muscle large area infarction, can not quickly eliminate again, then the life of people also just finishes.
Currently for the treatment of coronary heart disease, chemicals can alleviate disease pain soon, but generally has bigger side effect.Treating cardiopathic medicament categories on market a lot, treatment by Chinese herbs effect is better than Western medicine, and treatment coronary heart disease is had certain curative effect by conventional medicine, can alleviate certain symptom, but effect is uncertain.
Summary of the invention
For the defect of prior art, the present invention be directed to the present situation for the treatment of at present, it is provided that a kind of pharmaceutical preparation for treating coronary heart disease, have no side effect, effective.
Specifically, the concrete scheme of the present invention is achieved in that
First, inventor provides a kind of pharmaceutical preparation for treating coronary heart disease according to drug matching experience, and the Chinese medicine ingredients contained in prescription is: Rhizoma Acori Graminei, Borneolum Syntheticum, cooked Radix Notoginseng, Radix Codonopsis, the Radix Astragali, Fructus Arctii, Eupolyphaga Seu Steleophaga, Semen Plantaginis, Radix Salviae Miltiorrhizae, Rhizoma Cyperi, Herba Epimedii, Fructus Atriplicis Sibiricae, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Eupatorii, Rhizoma Dioscoreae, Fructus Tritici Levis, red back of the body Acanthaceous indigo, Herba Selaginellae, Caulis Zizaniae caduciflorae, Radix Glycyrrhizae.
Further, inventor provides a kind of pharmaceutical preparation for treating coronary heart disease according to drug matching experience, each raw material dosage of prescription all has good curative effect in the weight portion scope of the present invention, described formula and weight portion be: Rhizoma Acori Graminei 5-13 part, Borneolum Syntheticum 4-10 part, cooked Radix Notoginseng 13-26 part, Radix Codonopsis 10-20 part, Radix Astragali 12-23 part, Fructus Arctii 10-24 part, Eupolyphaga Seu Steleophaga 3-6 part, Semen Plantaginis 3-8 part, Radix Salviae Miltiorrhizae 8-14 part, Rhizoma Cyperi 5-10 part, Herba Epimedii 6-11 part, Fructus Atriplicis Sibiricae 3-7 part, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 5-9 part, Herba Eupatorii 4-9 part, Rhizoma Dioscoreae 10-20 part, Fructus Tritici Levis 11-17 part, red back of the body Acanthaceous indigo 5-11 part, Herba Selaginellae 5-10 part, Caulis Zizaniae caduciflorae 4-11 part, Radix Glycyrrhizae 6-10 part.
Further, the formula of above-mentioned weight portion is carried out preferably, reach superior technique effect, it is preferred that formula is: Rhizoma Acori Graminei 9 parts, Borneolum Syntheticum 7 parts, cooked Radix Notoginseng 20 parts, Radix Codonopsis 15 parts, the Radix Astragali 16 parts, Fructus Arctii 17 parts, Eupolyphaga Seu Steleophaga 4.5 parts, Semen Plantaginis 6 parts, Radix Salviae Miltiorrhizae 11 parts, Rhizoma Cyperi 7.5 parts, Herba Epimedii 8 parts, Fructus Atriplicis Sibiricae 5 parts, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 7 parts, Herba Eupatorii 6.5 parts, Rhizoma Dioscoreae 15 parts, Fructus Tritici Levis 14 parts, red back of the body Acanthaceous indigo 8 parts, Herba Selaginellae 7.5 parts, Caulis Zizaniae caduciflorae 7.5 parts, 8 parts of Radix Glycyrrhizae.Or Rhizoma Acori Graminei 8 parts, Borneolum Syntheticum 6 parts, cooked Radix Notoginseng 22 parts, Radix Codonopsis 16 parts, the Radix Astragali 17 parts, Fructus Arctii 18 parts, Eupolyphaga Seu Steleophaga 5 parts, Semen Plantaginis 6.5 parts, Radix Salviae Miltiorrhizae 12 parts, Rhizoma Cyperi 7.5 parts, Herba Epimedii 9 parts, Fructus Atriplicis Sibiricae 5 parts, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 7 parts, Herba Eupatorii 7 parts, Rhizoma Dioscoreae 15 parts, Fructus Tritici Levis 15 parts, red back of the body Acanthaceous indigo 7 parts, Herba Selaginellae 8 parts, Caulis Zizaniae caduciflorae 7.5 parts, 7 parts of Radix Glycyrrhizae.
In pharmaceutical preparation described above, the Chinese medicine used all uses its conventional medicinal part to be used as medicine, and the dosage of drug used is reasonable, and all medicines have, for treatment coronary heart disease, the effect treated preferably after share, especially treatment coronary heart disease with qi deficiency and blood stasis coronary heart disease.
The function of each taste Chinese crude drug used in the pharmaceutical preparation of the treatment coronary heart disease of the present invention is as follows:
Borneolum Syntheticum: acrid in the mouth, cold in nature.
Gui Jing: GUIXIN, spleen, lung meridian.
Function cures mainly: refreshment of having one's ideas straightened out, clearing away heat to alleviate pain.Fainting for calentura coma, convulsion, apoplexy syncope due to accumulation of phlegm, stagnation of QI sudden syncope, attacked by pestiferous factors is gone into a coma, and conjunctival congestion, aphtha, laryngopharynx swelling and pain, auditory meatus is suppurated.
Cooked Radix Notoginseng: sweet in the mouth, warm in nature.
Gui Jing: return liver, stomach warp.
Function cures mainly: dissipating blood stasis stops blooding, subduing swelling and relieving pain.For spitting blood, spit blood, epistaxis, to have blood in stool, metrorrhagia, traumatic hemorrhage, chest and abdomen twinge, tumbling and swelling.
Rhizoma Acori Graminei: acrid in the mouth and bitter, temperature, nontoxic.
Function cures mainly: the happy key of energy, kind ventilation, arresting enursis, antiabortive relieving restlessness is vexed, can control forgetful.
Radix Codonopsis: sweet in the mouth, property is put down.
Gui Jing: return spleen, lung meridian.
Function cures mainly: invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Fructus Arctii: acrid in the mouth, hardship, cold.
Gui Jing: attach to the lung and stomach meridians.
Function cures mainly: dispelling wind and heat pathogens, lung qi dispersing rash, resolving toxin and disinhibiting the throat.For anemopyretic cold, cough with copious phlegm, measles, rubella, laryngopharynx swelling and pain, mumps erysipelas, carbuncle sore tumefacting virus.
Eupolyphaga Seu Steleophaga: salty in the mouth, cold in nature.
Gui Jing: return Liver Channel.
Function cures mainly: removing blood stasis with potent drugs blood, reuniting the fractured tendons and bones, for injured bone, blood stasis amenorrhea, lump in the abdomen mass in the abdomen
Radix Salviae Miltiorrhizae: bitter in the mouth, is slightly cold.
Gui Jing: GUIXIN, Liver Channel.
Function cures mainly: blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, and clear away heart-fire relieving restlessness, removing heat from blood eliminating carbuncle, and for obstruction of qi in the chest and cardialgia, gastral cavity abdomen hypochondriac pain, abdominal mass abdominal mass is gathered, pyretic arthralgia pain, dysphoria and insomnia, menoxenia, and dysmenorrhea amenorrhea, skin infection swells and ache.
Herba Epimedii taste acrid, sweet, warm, return liver, kidney channel, kidney-replenishing, bone and muscle strengthening, wind-damp dispelling, and for impotence and seminal emission, muscles and bones flaccidity is soft, rheumatic arthralgia, numbness contracture, climacteric hypertension.
Fructus Atriplicis Sibiricae: acrid in the mouth, warm in nature.
Function with cure mainly: suppressing the hyperactive liver resolving depression, promoting blood circulation by removing wind, improving eyesight is antipruritic for dizziness of having a headache, distending pain in the chest and hypochondrium, and breast closes acute mastitis, cataract, rubella pruritus.
Lagotis clarkei Hook. F (Lagotis brevituba Maxim.): bitter in the mouth, cold in nature.
Function cures mainly: heat-clearing and toxic substances removing, blood pressure lowering, regulating menstruation.Main acute, chronic hepatitis；Nephritis；Lung abscess；Hypertension；The moon is often uncomfortable；Breast carcinoma.
Herba Eupatorii: acrid in the mouth, property is put down.
Gui Jing: return spleen, stomach, lung meridian.
Function cures mainly: removing dampness by means of aromatics, appetizing of being amusing, and delivers expelling summer-heat.For turbid damp obstructing in middle-JIAO, gastral cavity painful abdominal mass vomiting and nausea, sweet greasy in mouth, halitosis, sialism, heat-damp in summer table disease, feeling of fullness in the head is uncomfortable in chest.
Rhizoma Dioscoreae: sweet in the mouth, property is put down.
Gui Jing: return spleen, lung, kidney channel.
Function cures mainly: spleen reinforcing nourishing the stomach, and promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission.For insufficiency of the spleen lack of appetite, incessant chronic diarrhea, the deficiency of the lung is breathed with cough, emission due to deficiency of the kidney, leukorrhagia, frequent micturition, and deficiency-heat is quenched one's thirst.Rhizoma Dioscoreae (parched with bran) spleen reinforcing stomach invigorating.For insufficiency of the spleen lack of appetite, loose stool of having loose bowels, leukorrhagia.
Semen Plantaginis: sweet in the mouth, cold in nature.
Gui Jing: return liver, kidney, lung, small intestine meridian.
Function cures mainly: clearing away heat and promoting diuresis, and eliminating dampness by diuresis is treating stranguria, and improving eyesight is eliminated the phlegm.For edema distension, the puckery pain of pyretic stranguria, diarrhea due to summer heat and dampness, conjunctival congestion and swelling pain, phlegm-heat cough.
Fructus Tritici Levis: sweet in the mouth, cool in nature.
Gui Jing: GUIXIN warp.
Effect: dispel deficiency-heat, YIN nourishing and the production of body fluid promoting, improve immune defenses, improve the ability of low antitumor especially gastric cancer.
Red back of the body Acanthaceous indigo: bitter in the mouth, property is put down
Function cures mainly: promoting blood circulation to remove blood stasis；Heat-clearing and toxic substances removing.Main menoxenia；Prolonged lochia；Hygropyretic dysentery；Furuncle carbuncle；Traumatic injury；Fracture
Herba Selaginellae: acrid in the mouth, property is put down.
Gui Jing: return liver, heart channel.
Function cures mainly: promoting blood circulation to restore menstrual flow.For amenorrhea dysmenorrhea.Abdominal mass mass in the abdomen, injury from falling down.Herba Selaginellae charcoal removing stasis to stop bleeding.For spitting blood, metrorrhagia, have blood in stool, proctoptosis.
Radix Glycyrrhizae: sweet in the mouth, property is put down.
Gui Jing: enter spleen, stomach, the heart, lung meridian.
Function cures mainly: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain.
Rhizoma Cyperi: bitter in the mouth, property is put down.
Gui Jing: return liver, spleen, tri-jiao channel.
Function cures mainly: promoting QI circulation for relieving depression, menstruction regulating and pain relieving.For stagnation of QI due to depression of the liver, breast, the side of body, abdominal distention, dyspepsia, breast gastral cavity painful abdominal mass is vexed, and colic of cold type is suffered from abdominal pain, distending pain of the breast, menoxenia, amenorrhea dysmenorrhea.
The Radix Astragali: sweet in the mouth, warm in nature.
Gui Jing: return lung, spleen channel.
Function cures mainly: invigorating QI to consolidate the body surface resistance, diuresis toxin expelling, weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, and carbuncle difficulty is burst, and bursts for a long time and does not hold back, and blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst.
Radix Codonopsis: sweet in the mouth, property is put down.
Gui Jing: return spleen, lung meridian.
Function cures mainly: invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Caulis Zizaniae caduciflorae: sweet in the mouth；Cold in nature
Gui Jing: liver；Spleen；Lung meridian
Function cures mainly: relieving heat toxin；Relieving thirst and restlessness；Profit two is just.Main dysphoria with smothery sensation；Quench one's thirst；Constipation and anuresis；Jaundice；Dysentery；Pyretic stranguria；Conjunctival congestion；Breast antiperspirant not under；Skin infection
The pharmaceutical dosage form of the present invention one in granule, capsule, tablet, injection, tincture, suppository, pill, syrup, mixture, powder, lotion, membrane, drop pill.More preferably capsule.
Above prescription through conscientious research, the reasonability according to middle medical drugs, the preparation method inventors herein proposing concrete a kind of pharmaceutical preparation treating coronary heart disease, is concretely comprised the following steps by the present invention:
(1) take Semen Plantaginis, Rhizoma Acori Graminei, Borneolum Syntheticum, Fructus Atriplicis Sibiricae, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Eupatorii, Rhizoma Dioscoreae, Fructus Tritici Levis, red back of the body Acanthaceous indigo, Herba Selaginellae and Caulis Zizaniae caduciflorae and soak 1.5 hours, the boiled 10min of intense fire, slow fire 30-60min, decoct twice, being evaporated to 90 DEG C, density is the extractum of 1.10, standby；
(2) take Eupolyphaga Seu Steleophaga, Rhizoma Cyperi, Herba Epimedii, Radix Glycyrrhizae grind to form coarse powder and add 70% ethanol extraction 2 times, each 2 hours, merge medicinal liquid, stand 24 hours, standby；
(3) take Radix Codonopsis, the Radix Astragali, Fructus Arctii and Radix Salviae Miltiorrhizae powder and be broken into appropriate 70% ethanol extraction of fine powder 2 times, each 1.5 hours, collect extracting solution, merge medicinal liquid, stand 24 hours, standby；
(4) taking the supernatant prepared in (2nd) and (3) step, decompression recycling ethanol, be concentrated into 70 DEG C, density is the extractum of 1.03, standby；
(5) the extractum mix homogeneously of step (1) and (4) is added cooked Radix Notoginseng and obtain mixture, prepare into pharmaceutical preparation with pharmaceutically acceptable adjuvant.
Water and the ratio of medical material described in step (1) are 3:1；
Pharmaceutical preparation in above-mentioned preparation method, granule, powder, capsule, pill, tablet and clinically acceptable dosage form are prepared in described pharmaceutical preparation.Wherein the preparation of capsule is the mixture adding the lactose of step (5) mixture weight 10% and dextrin, in the mixture of lactose and dextrin lactose and and the weight ratio of dextrin be 1:1；Stir heating to 75 DEG C, granulates, dry and load capsule, obtaining capsule, capsule weight 200mg；The adjuvant of granule can be select in cane sugar powder, Carboxymethyl cellulose sodium, dextrin and correctives etc.；Powder can select from starch, kaolin, calcium phosphate, precipitated calcium carbonate etc.；The adjuvant of pill can select from starch, microcrystalline Cellulose, pregelatinized Starch etc.；The adjuvant of tablet can select from starch, dextrin, microcrystalline Cellulose, pregelatinized Starch, magnesium stearate, lactose, Icing Sugar, carboxymethylstach sodium etc..
Compared with prior art, the present invention treats the capsule of coronary heart disease and has the advantage that
The preparation of medicine of the present invention compared with prior art, focuses on theory of Chinese medical science, and all medicines are combined tool and consolidated effect of mark, multiple positive evil removing, monarch is various, negative and positive are balanced, focus on the coordination of function of the internal organs such as kidney, the heart, liver, spleen, blood fat reducing anticoagulant, reduction blood viscosity simultaneously, thrombus, all medicines are collocated with each other and reach to improve blood circulation, release vasospasm, arteriosclerosis, cardiovascular system diseases can be effectively treated, make drug effect and function more fully treating both the principal and secondary aspects of a disease.
Specific embodiment
It is obvious to a person skilled in the art that the details of the embodiment of the present invention, and when without departing substantially from the spirit of the present invention or basic feature, it is possible to realize the present invention in other specific forms.Embodiment all should be regarded as exemplary, and be nonrestrictive, it is intended that all changes in the implication of the equivalency dropping on claim and scope are included in the present invention.
Embodiment 1: a kind of capsule treating coronary heart disease, including following weight portion Chinese crude drug:
Rhizoma Acori Graminei 5-13 gram, Borneolum Syntheticum 4-10 gram, cooked Radix Notoginseng 13-26 gram, Radix Codonopsis 10-20 gram, Radix Astragali 12-23 gram, Fructus Arctii 10-24 gram, Eupolyphaga Seu Steleophaga 3-6 gram, Semen Plantaginis 3-8 gram, Radix Salviae Miltiorrhizae 8-14 gram, Rhizoma Cyperi 5-10 gram, Herba Epimedii 6-11 gram, Fructus Atriplicis Sibiricae 3-7 gram, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 5-9 gram, Herba Eupatorii 4-9 gram, Rhizoma Dioscoreae 10-20 gram, Fructus Tritici Levis 11-17 gram, red back of the body Acanthaceous indigo 5-11 gram, Herba Selaginellae 5-10 gram, Caulis Zizaniae caduciflorae 4-11 gram, 6-10 gram of Radix Glycyrrhizae.
Concrete preparation method is:
(1) take Semen Plantaginis, Rhizoma Acori Graminei, Borneolum Syntheticum, Fructus Atriplicis Sibiricae, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Eupatorii, Rhizoma Dioscoreae, Fructus Tritici Levis, red back of the body Acanthaceous indigo, Herba Selaginellae and Caulis Zizaniae caduciflorae add water (ratio of water and medical material is 3:1) soak 1.5 hours, the boiled 10min of intense fire, slow fire 30-60min, decoct twice, it is evaporated to 90 DEG C, density is the extractum of 1.10, standby；
(2) take Eupolyphaga Seu Steleophaga, Rhizoma Cyperi, Herba Epimedii, Radix Glycyrrhizae grind to form coarse powder and add 70% ethanol extraction 2 times, each 2 hours, merge medicinal liquid, stand 24 hours, standby；
(3) take Radix Codonopsis, the Radix Astragali, Fructus Arctii and Radix Salviae Miltiorrhizae powder and be broken into appropriate 70% ethanol extraction of fine powder 2 times, each 1.5 hours, collect extracting solution, merge medicinal liquid, stand 24 hours, standby；
(4) taking the supernatant prepared in (2nd) and (3) step, decompression recycling ethanol, be concentrated into 70 DEG C, density is the extractum of 1.03, standby；
(5) the extractum mix homogeneously of step (1) and (4) is added cooked Radix Notoginseng and obtains mixture, add the lactose of mixture weight 10% and the mixture of dextrin, in the mixture of lactose and dextrin lactose and and the weight ratio of dextrin be 1:1；Stir heating to 75 DEG C, granulates, dry and load capsule, obtaining capsule, capsule weight 200mg.
Embodiment 2: a kind of capsule treating coronary heart disease, including following weight portion Chinese crude drug:
Rhizoma Acori Graminei 5-13 gram, Borneolum Syntheticum 4-10 gram, cooked Radix Notoginseng 13-26 gram, Radix Codonopsis 10-20 gram, Radix Astragali 12-23 gram, Fructus Arctii 10-24 gram, Eupolyphaga Seu Steleophaga 3-6 gram, Semen Plantaginis 3-8 gram, Radix Salviae Miltiorrhizae 8-14 gram, Rhizoma Cyperi 5-10 gram, Herba Epimedii 6-11 gram, Fructus Atriplicis Sibiricae 3-7 gram, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 5-9 gram, Herba Eupatorii 4-9 gram, Rhizoma Dioscoreae 10-20 gram, Fructus Tritici Levis 11-17 gram, red back of the body Acanthaceous indigo 5-11 gram, Herba Selaginellae 5-10 gram, Caulis Zizaniae caduciflorae 4-11 gram, 6-10 gram of Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 3: a kind of capsule treating coronary heart disease, including following weight portion Chinese crude drug:
Rhizoma Acori Graminei 9 grams, Borneolum Syntheticum 7 grams, cooked Radix Notoginseng 20 grams, Radix Codonopsis 15 grams, the Radix Astragali 16 grams, Fructus Arctii 17 grams, Eupolyphaga Seu Steleophaga 4.5 grams, Semen Plantaginis 6 grams, Radix Salviae Miltiorrhizae 11 grams, Rhizoma Cyperi 7.5 grams, Herba Epimedii 8 grams, Fructus Atriplicis Sibiricae 5 grams, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 7 grams, Herba Eupatorii 6.5 grams, Rhizoma Dioscoreae 15 grams, Fructus Tritici Levis 14 grams, red back of the body Acanthaceous indigo 8 grams, Herba Selaginellae 7.5 grams, Caulis Zizaniae caduciflorae 7.5 grams, 8 grams of Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 4: a kind of capsule treating coronary heart disease, including following weight portion Chinese crude drug:
Rhizoma Acori Graminei 8 grams, Borneolum Syntheticum 6 grams, cooked Radix Notoginseng 22 grams, Radix Codonopsis 16 grams, the Radix Astragali 17 grams, Fructus Arctii 18 grams, Eupolyphaga Seu Steleophaga 5 grams, Semen Plantaginis 6.5 grams, Radix Salviae Miltiorrhizae 12 grams, Rhizoma Cyperi 7.5 grams, Herba Epimedii 9 grams, Fructus Atriplicis Sibiricae 5 grams, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 7 grams, Herba Eupatorii 7 grams, Rhizoma Dioscoreae 15 grams, Fructus Tritici Levis 15 grams, red back of the body Acanthaceous indigo 7 grams, Herba Selaginellae 8 grams, Caulis Zizaniae caduciflorae 7.5 grams, 7 grams of Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 5: animal model test
TONGXINLUO JIAONANG is mainly composed of the processed capsules made of flavour of a drug such as Radix Ginseng, Hirudo, Scorpio, Lignum Santali Albi, Eupolyphaga Seu Steleophaga, Scolopendra, Periostracum Cicadae.Treating coronary heart disease, angina pectoris etc., apoplexy hat only heart network belongs in angina pectoris that insufficiency of heart-QI is weary, blood stasis network resistance disease, and disease is seen chest tightness, twinge, angor, fixing do not moved, cardiopalmus spontaneous perspiration, shortness of breath and fatigue, purplish tongue or have ecchymosis, thready and hesitant pulse or knot generation.The present invention is used for doing positive control test.
5.1, syndrome of blood stasis due to qi deficiency modeling and administration
Selecting healthy Wistar rat, male and female are regardless of, (18 ± 3) moon at monthly age, body weight 280～340g, adopt hunger, fatigue, cold-damp, the terrified and multifactor modeling 10d of high fat diet.Result shows: model mouse the deficiency of vital energys such as asthenia is drowsiness, anorexia, hypotrichosis easily take off and the blood stasis symptom such as the dark reddish purple stasis of blood dim, the subcutaneous purple of body of the tongue or blue patch occurs and loses weight, and drinking-water food-intake reduces the success of blood stasis due to qi deficiency mouse modeling.
Blank group gives normal diet, model control group and 4 treatment groups and gives hungry nursing, and appetite is the 55% of the every Day feeding amount of normal mouse, and feedstuff is high lipid food, and the modeling cycle is 4 weeks.Dosage is by the dosage after adult's routine dose conversion.TONGXINLUO JIAONANG gavage 3g/kg, basic, normal, high dosage group gavage 1.5,3,6g/kg successively of capsule of the present invention, respectively A, B, C group, blank group and model control group give normal saline, equal 1 day 1 time, successive administration 4 weeks.
5.2, the foundation of myocardial infarction and ischemia model
After syndrome of blood stasis due to qi deficiency modeling end cycle, carry out the duplication of myocardial infarction and ischemia model.Press 30 units/kg dosage injection of pituitrin for 6 groups, record injection time, after 15min, urethane 1 μ g/g anesthetized mice, II lead electrocardiogram of certain time after electrocardiograph record injected in mice pituitrin, by software records data, observe heart rate and the change of T wave height judges that whether myocardial ischemia modeling is successful.Such as table 1
5.3, Testing index
Thromboxane B2 (TXB2) and 6 ketone PGF1αs (6-keto-PGF1 α) are the common counters of a pair reflection platelet aggregation and vasoconstriction diastole.After Electrocardiography completes, plucking eyeball of mouse immediately and take blood, blood, without any process, is placed in room temperature.The centrifugal 15min of 3500r/min under low temperature, takes upper serum detection TXB2,6-keto-PGF1 alpha content, and operation carries out in strict accordance with test kit description.Microplate reader measures absorbance, carries out data statistics.Such as table 2.
5.4, statistical method
SPASS22.0 statistical analysis software is adopted to process.
Heart rate and the T wave height of mice respectively organized by table 1
| Heart rate/(secondary/min) | T wave amplitude/mV | |
| Blank group | 363.39±25.36 | 0.269±0.059 |
| Model control group | 401.27±22.36## | 0.209±0.077## |
| Positive controls | 397.69±21.54## | 0.127±0.063## |
| C group | 390.27±18.65## | 0.125±0.071## |
| B group | 395.38±19.36## | 0.128±0.054## |
| A group | 392.22±22.10## | 0.130±0.049## |
Note:
Compared with blank group,#P < 0.05,##P < 0.01；
As it can be seen from table 1 blank group is compared with model control group, positive controls and A, B, C group, there is significant difference (P < 0.01), blood stasis due to qi deficiency model mice modeling success is described.
TXB respectively organized by table 22And 6-keto-PGF1α
Note:
Compared with model control group,P < 0.05,P < 0.01；
Compared with positive controls,▲P < 0.05.
From table 2 it can be seen that TXB2And 6-keto-PGF1αBlank group is compared with model control group, there is significant difference (P < 0.01), positive controls and A, B, C group are compared with model control group, it is respectively provided with significant difference (P < 0.05 or P < 0.01), wherein C group has significant difference (P < 0.05) compared with positive controls, and the capsule being further characterized by the present invention is suitable for further clinical trial.
Embodiment 6: animal model test and experiment in vitro
The capsule of the embodiment 3 used in the capsule alternate embodiment 6 that embodiment 1,2,4 is prepared, repeat embodiment 5, found that the capsule of embodiment 1,2,4 preparation is still equally authentic at the therapeutic effect for the treatment of syndrome of blood stasis due to qi deficiency coronary heart disease, further demonstrate that the weight portion Chinese crude drug of the present invention effect in treatment group.
Embodiment 7: clinical trial
7.1, physical data
Moving in hospital January from January, 2009～2015 year, Cardiological 213 example cardiovascular neurosis patient is selected object, 25～60 years old age, average 41.5 years old, wherein male 109 examples, female 104 example；The course of disease February～13 years, average course of disease 2.47.Being divided into two groups, respectively treatment group and observation group, between two groups, the factor such as sex, the state of an illness, diet there was no significant difference (P > 0.05).
7.2, diagnostic criteria
Equal main suit cardiopalmus, dyspnea, precordialgia or heart autonomic nervous dysfunction symptom (hyperhidrosis, brothers feel cold, both hands tremble, frequent micturition etc.), with dreaminess, insomnia, vexed, dizzy, tinnitus etc.；By detailed physical examination and necessary auxiliary examination, get rid of various organic heart disease；And formulate with reference to " the clinical trial guideline of new Chinese medicine treatment cardiopalmus ", " traditional Chinese medical science cardiopathia Standardization of diagnosis and curative effect and medication specification ".The traditional Chinese medical science with cardiopalmus, breathe hard, uncomfortable in chest, the big symptom of chest pain four is for starting point exclusion standard: have the important organ illness such as brain, lung, liver, kidney；Patient and family members thereof disagree into electing object of study as.
7.3, test method
] treatment the last fortnight disable other anti-insomnia medicine.
Treatment group: 107 examples, male 55 examples, female 52 example, adopt the capsule of Medications Example 3 of the present invention to treat.Every day 2 times, each 3,10 days courses for the treatment of, continuous 3 courses for the treatment of, follow up a case by regular visits to 6 months.
Matched group: 106 examples, male 54 examples, female 52 example, multiple heart-soothing capsule is administered orally. once 2-4 grain. 3 times on the one., glad health slow releasing tablet once a day, one time 1,10 days courses for the treatment of, continuous 3 courses for the treatment of, follow up a case by regular visits to 6 months.
7.3, the evaluation of curative effect
Cure: subjective symptoms all disappears, and does not affect work and life；
Taking a turn for the better: subjective symptoms partial disappearance, slight effect works and life；
Invalid: subjective symptoms is without improving or increasing the weight of；
Relapse rate: the individuality that (cure+take a turn for the better) recurs again/(cure+take a turn for the better).
7.4, statistical method
All data inputting SPSS22.0 statistical software, statistically significant with P < 0.05 for difference.
7.5, result
Two groups of patient's curative effects relatively see shown in table 3 below.
The comparison sheet of 3 liang of table group patient's curative effect
| Group | Cure | Effectively | Invalid | Effective percentage (%) | Relapse rate (%) |
| Treatment group | 71 | 33 | 3 | 97.2 | 1.9 |
| Observation group | 35 | 37 | 34 | 67.9 | 13.9 |
Conclusion:
As can be seen from Table 3, treatment group cures 71 examples, effective 33 examples, invalid 3 examples, recurs 2 examples, total effective rate 97.2%, relapse rate 1.9%；Observation group cures 35 examples, effective 37 examples, invalid 34 examples, recurs 10 examples, total effective rate 67.9%, relapse rate 13.9%.The curative effect of the above-mentioned visible test group of analytic statistics result is substantially better than matched group, and total effective rate test group is also significantly better than matched group, it is seen that coronary heart disease with qi deficiency and blood stasis can effectively be treated by medicine of the present invention.
7.6, model case
Case 1: cattle, man, 63 years old, people from Linyi, Shandong, retired professor, over 2013, my institute checks, patient's private prosecution has hyperlipidemia premature coronary heart disease to have 3 years, pant steadily, but slight work is relievingd asthma, breath just increases the weight of, breast is vexed, hectic fever, night sweat, unconscious obstacle and the dyskinesia, above-mentioned situation often occurs recently, the tired phenomenon of patient's heart is obvious, dyspnea, take multiple western medicine result not good, institute treat to me, take the capsule of the embodiment of the present invention 3, after 30 days, coronary heart disease symptom is clearly better, continue to take drug withdrawal in 60 days, patient pants steadily, the heart is tired to take a turn for the better, basic healing, follow up a case by regular visits to not recurrence in 1 year.
Case 2: Ma, female 56 years old, Yancheng, Jiangsu Province people, over 20142, my institute checks, there is sensation of oppression over the chest with shortness of breath and dizziness in patient's private prosecution, time with cardiopalmus, aggravation time tired, can alleviating through having a rest, outpatient service measuring blood pressure of once repeatedly seeing a doctor finds hypertension, reaches as high as 190/110mmHg.Look into electrocardiogram prompting " deficiency myocardial blood supply ", diagnose as coronary heart disease, type-II diabetes, essential hypertension, introduces through friend, institute treats to me, take the capsule of the embodiment of the present invention 3, after 30 days, coronary heart disease symptom is clearly better, and continues to take drug withdrawal in 60 days, patient pants steadily, the heart is tired to take a turn for the better, and substantially cures, and follows up a case by regular visits to not recurrence in 1 year.
Embodiment 8: toxicity is verified
8.1, acute toxicity test
Tested Chinese medicine preparation: the capsule manufactured by embodiment of the present invention 1-4, adds purified water by 1:2, makes solution, standby.Experimental animal: regular grade kunming mice, body weight 20g ± 5g, male and female half and half, female mice is all without pregnant.
The solution of mouse stomach Chinese medicine capsules preparation of the present invention, when given low reaches 735.5g crude drug/kg dosage, after administration, mice occurs that light activity reduces, 1 hours recovers normal, Continuous Observation 7 days after administration, none animal dead, its overall health of patients, diet, take the photograph water, urine and body weight increase all normal.
8.1.1, result of the test shows
The maximum dosage-feeding of the capsule manufactured by mouse stomach embodiment 1-4 is 735.5g crude drug/kg/d (LD50 > 735.5g crude drug/kg).The Chinese medicine powder clinical application every day total amount of the present invention is 0.15g crude drug/kg/d to the maximum；By weighing machine, the dosis tolerata of mouse stomach capsule is 4903.3 times of clinical patient.Point out this medicine acute toxicity extremely low, clinical drug safety.
8.2, long-term toxicity test for animals
Tested Chinese medicine preparation: embodiment of the present invention 2-4 gained Chinese medicine capsules, adds purified water by 1:2, makes solution, standby.Experimental animal: regular grade SD rat, body weight 210g ± 14g, male and female half and half, female rats is all without pregnant.
8.2.2, method and result:
3 kinds of Chinese medicine capsules: be divided into high, medium and low three dosage groups, per weight dosage respectively the 180 of patient's dose, 60,20 times；Experimental mouse is randomly divided into 10 groups, and wherein the capsule solution of 9 groups of difference 3 kinds of three dosage of gavage, remains 1 group of gavage normal saline (40 times of patient's dose)；All 10 groups of gavages 180 days all continuously, observe animal general toxic reaction and the order of severity, and place after death checks each position by rule of operation, and carries out hematology, the pathological examination of the main organs such as ALT, BUN and the heart, liver, spleen, lung, kidney, stomach；Through long-term feeding, all there is not toxic reaction in 10 groups of rats.Physically well develop.Macroscopic appearance and main organs no abnormality seen.Peripheral hemogram and Serum ALT, BUN compare with matched group without pathologic change.The all not significant changes such as the pathological replacement heart, liver, spleen, lung, kidney, stomach, it is therefore contemplated that through proved by pathology, animal is showed by 3 kinds of Chinese medicine capsules without chronic toxicity.
By two above toxicity test, it was demonstrated that the present invention is safe by the embodiment 1-4 Chinese medicine capsules made, and has no side effect, it is possible to taken by patient.
8.3, human toxicity test
Randomly draw medical (Disease) patient 100 example, 25～60 years old age, average 41.5 years old, wherein male 109 examples, female 104 example；The course of disease February～13 years, average course of disease 2.47, carry out toxicity assessment.
8.3.2, toxicity assessment
Health check-up of each do after continuing one month with drug administration before medication, health check-up project:
(1) general health check-up project: temperature pulse respiration；
(2) blood, urine, stool routine examination inspection, each before and after treatment make once；
(3) liver function AST, ALT；Renal function BUN, CR and blood glucose；Cardiac function CPK, LDH, EKG；Coagulation function and platelet.
8.3.3, to toxicity assessment classification, standard is as follows:
0 grade: avirulence Symptoms；
L level: mild toxicity Symptoms；
2 grades: moderate signs of toxicity shows；
3 grades: serious toxicity Symptoms；
4 grades: threat to life signs of toxicity shows；
Draw according to physical examination result analysis, in 100 examples (Disease) patient, 0 grade of 89 people, 1 grade of 11 people, 3 grade of 0 people, 4 grade of 0 people.
It can be seen that pharmaceutical preparation of the present invention can efficiently control the pathological changes process of (Disease) from curative effect and toxicity assessment, and toxic and side effects is less.
In the 100 example patients observed, only have 1 example laxativeness after taking Chinese medicine of the present invention, occur that the probability of side reaction is little.
Claims (9)
1. the pharmaceutical preparation being used for treating coronary heart disease, it is characterized in that, described pharmaceutical preparation includes following Chinese crude drug: Rhizoma Acori Graminei, Borneolum Syntheticum, cooked Radix Notoginseng, Radix Codonopsis, the Radix Astragali, Fructus Arctii, Eupolyphaga Seu Steleophaga, Semen Plantaginis, Radix Salviae Miltiorrhizae, Rhizoma Cyperi, Herba Epimedii, Fructus Atriplicis Sibiricae, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Eupatorii, Rhizoma Dioscoreae, Fructus Tritici Levis, red back of the body Acanthaceous indigo, Herba Selaginellae, Caulis Zizaniae caduciflorae, Radix Glycyrrhizae.
2. pharmaceutical preparation according to claim 1, it is characterized in that, described pharmaceutical preparation includes following weight portion Chinese crude drug: Rhizoma Acori Graminei 5-13 part, Borneolum Syntheticum 4-10 part, cooked Radix Notoginseng 13-26 part, Radix Codonopsis 10-20 part, Radix Astragali 12-23 part, Fructus Arctii 10-24 part, Eupolyphaga Seu Steleophaga 3-6 part, Semen Plantaginis 3-8 part, Radix Salviae Miltiorrhizae 8-14 part, Rhizoma Cyperi 5-10 part, Herba Epimedii 6-11 part, Fructus Atriplicis Sibiricae 3-7 part, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 5-9 part, Herba Eupatorii 4-9 part, Rhizoma Dioscoreae 10-20 part, Fructus Tritici Levis 11-17 part, red back of the body Acanthaceous indigo 5-11 part, Herba Selaginellae 5-10 part, Caulis Zizaniae caduciflorae 4-11 part, Radix Glycyrrhizae 6-10 part.
3. pharmaceutical preparation according to claim 1, it is characterized in that, described pharmaceutical preparation includes following weight portion Chinese crude drug: Rhizoma Acori Graminei 9 parts, Borneolum Syntheticum 7 parts, cooked Radix Notoginseng 20 parts, Radix Codonopsis 15 parts, the Radix Astragali 16 parts, Fructus Arctii 17 parts, Eupolyphaga Seu Steleophaga 4.5 parts, Semen Plantaginis 6 parts, Radix Salviae Miltiorrhizae 11 parts, Rhizoma Cyperi 7.5 parts, Herba Epimedii 8 parts, Fructus Atriplicis Sibiricae 5 parts, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 7 parts, Herba Eupatorii 6.5 parts, Rhizoma Dioscoreae 15 parts, Fructus Tritici Levis 14 parts, red back of the body Acanthaceous indigo 8 parts, Herba Selaginellae 7.5 parts, Caulis Zizaniae caduciflorae 7.5 parts, 8 parts of Radix Glycyrrhizae.
4. pharmaceutical preparation according to claim 1, it is characterized in that, described pharmaceutical preparation includes following weight portion Chinese crude drug: Rhizoma Acori Graminei 8 parts, Borneolum Syntheticum 6 parts, cooked Radix Notoginseng 22 parts, Radix Codonopsis 16 parts, the Radix Astragali 17 parts, Fructus Arctii 18 parts, Eupolyphaga Seu Steleophaga 5 parts, Semen Plantaginis 6.5 parts, Radix Salviae Miltiorrhizae 12 parts, Rhizoma Cyperi 7.5 parts, Herba Epimedii 9 parts, Fructus Atriplicis Sibiricae 5 parts, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 7 parts, Herba Eupatorii 7 parts, Rhizoma Dioscoreae 15 parts, Fructus Tritici Levis 15 parts, red back of the body Acanthaceous indigo 7 parts, Herba Selaginellae 8 parts, Caulis Zizaniae caduciflorae 7.5 parts, 7 parts of Radix Glycyrrhizae.
5. pharmaceutical preparation according to claim 1, it is characterised in that: described pharmaceutical dosage form one in granule, capsule, tablet, injection, tincture, suppository, pill, syrup, mixture, powder, lotion, membrane, drop pill.
6. pharmaceutical preparation according to claim 5, it is characterised in that described pharmaceutical dosage form is selected from capsule, and the weight of capsule is 200mg.
7. the preparation method of the pharmaceutical preparation described in a claim 1, it is characterised in that concrete step is:
(1) take Semen Plantaginis, Rhizoma Acori Graminei, Borneolum Syntheticum, Fructus Atriplicis Sibiricae, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Eupatorii, Rhizoma Dioscoreae, Fructus Tritici Levis, red back of the body Acanthaceous indigo, Herba Selaginellae and Caulis Zizaniae caduciflorae and soak 1.5 hours, the boiled 10min of intense fire, slow fire 30-60min, decoct twice, being evaporated to 90 DEG C, density is the extractum of 1.10, standby；
(2) take Eupolyphaga Seu Steleophaga, Rhizoma Cyperi, Herba Epimedii and Radix Glycyrrhizae to grind to form coarse powder and add 70% ethanol extraction 2 times, each 2 hours, merge medicinal liquid, stand 24 hours, standby；
(3) take Radix Codonopsis, the Radix Astragali, Fructus Arctii and Radix Salviae Miltiorrhizae powder and be broken into appropriate 70% ethanol extraction of fine powder 2 times, each 1.5 hours, collect extracting solution, merge medicinal liquid, stand 24 hours, standby；
(4) taking the supernatant prepared in (2nd) and (3) step, decompression recycling ethanol, be concentrated into 70 DEG C, density is the extractum of 1.03, standby；
(5) the extractum mix homogeneously of step (1) and (4) is added cooked Radix Notoginseng and obtain mixture, prepare into pharmaceutical preparation with pharmaceutically acceptable adjuvant.
8. pharmaceutical preparation according to claim 1, it is characterised in that described pharmaceutical preparation purposes in the medicine in preparation treatment coronary heart disease.
9. pharmaceutical preparation according to claim 1, it is characterised in that described pharmaceutical preparation purposes in the medicine at preparation treatment coronary heart disease with qi deficiency and blood stasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610127979.8A CN105770520A (en) | 2016-03-07 | 2016-03-07 | Medicine preparation used for treating coronary heart disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610127979.8A CN105770520A (en) | 2016-03-07 | 2016-03-07 | Medicine preparation used for treating coronary heart disease and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105770520A true CN105770520A (en) | 2016-07-20 |
Family
ID=56387245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610127979.8A Withdrawn CN105770520A (en) | 2016-03-07 | 2016-03-07 | Medicine preparation used for treating coronary heart disease and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105770520A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138618A (en) * | 2016-08-18 | 2016-11-23 | 徐伟俊 | One treats anginal Chinese and western medicinal composition and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285328A (en) * | 2012-03-31 | 2013-09-11 | 李浩成 | Traditional Chinese medicine composition capsule for treating coronary heart diseases and preparation method thereof |
| CN105233075A (en) * | 2015-11-20 | 2016-01-13 | 张永江 | Traditional Chinese medicine combination treating coronary heart disease |
-
2016
- 2016-03-07 CN CN201610127979.8A patent/CN105770520A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285328A (en) * | 2012-03-31 | 2013-09-11 | 李浩成 | Traditional Chinese medicine composition capsule for treating coronary heart diseases and preparation method thereof |
| CN105233075A (en) * | 2015-11-20 | 2016-01-13 | 张永江 | Traditional Chinese medicine combination treating coronary heart disease |
Non-Patent Citations (1)
| Title |
|---|
| 何华等: "《李鲤学术思想与临证经验》", 31 January 2015, 人民军医出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138618A (en) * | 2016-08-18 | 2016-11-23 | 徐伟俊 | One treats anginal Chinese and western medicinal composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101856482B (en) | Pure Chinese medicinal preparation for treating mental illness and preparation method thereof | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN103230457B (en) | A kind of Chinese medicine composition treating viral myocarditis and preparation method thereof and purposes | |
| CN102743455B (en) | Chinese patent medicine for treating diabetes mellitus | |
| CN114224998A (en) | Traditional Chinese medicine composition for treating spleen-kidney yang deficiency type functional dyspepsia, preparation and application | |
| CN112316051B (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN104324134B (en) | One kind improves microcirculatory Chinese medicine composition and preparation method thereof | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN105727158A (en) | Traditional Chinese medicinal capsule for treating lymphoma, and preparation method thereof | |
| CN103349709B (en) | Traditional Chinese medicine preparation capable of tonifying qi and yin and nourishing liver and kidney | |
| CN103330911B (en) | Chinese medicine powder for treating coronary heart disease and preparation method thereof | |
| CN102362957B (en) | Chinese prepared medicine for treating deep lupus erythematosus | |
| CN108721528A (en) | A kind of Chinese medicinal capsule for treating hypertension | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN105288143A (en) | Traditional Chinese medicine composition for treating asthma | |
| CN104758888A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104547695B (en) | It is a kind of for treating the pharmaceutical composition and its application of trigeminal neuralgia | |
| CN103356970A (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia | |
| CN104667129A (en) | Medicine for treating rheumatic heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160720 |
|
| WW01 | Invention patent application withdrawn after publication |